---
title: "SMMT: Ivonescimab achieved landmark Phase III survival results and FDA BLA acceptance, with strong cash reserves"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293661481.md"
description: "Ivonescimab demonstrated significant overall survival benefits in multiple Phase III NSCLC trials, with consistent efficacy across regions and a strong safety profile. Financially, cash reserves remain robust at $690.7 million, and the FDA accepted the BLA for ivonescimab, with a decision expected in November 2026.Original document: Summit Therapeutics Inc. [SMMT] SEC 8-K Current Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T20:12:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293661481.md)
  - [en](https://longbridge.com/en/news/293661481.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293661481.md)
---

# SMMT: Ivonescimab achieved landmark Phase III survival results and FDA BLA acceptance, with strong cash reserves

Ivonescimab demonstrated significant overall survival benefits in multiple Phase III NSCLC trials, with consistent efficacy across regions and a strong safety profile. Financially, cash reserves remain robust at $690.7 million, and the FDA accepted the BLA for ivonescimab, with a decision expected in November 2026.

Original document: Summit Therapeutics Inc. \[SMMT\] SEC 8-K Current Report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

- [Summit Therapeutics Q2 net loss narrows on lower stock compensation](https://longbridge.com/en/news/293662165.md)
- [Summit Therapeutics announces availability of ivonescimab HARMONi trial update press release](https://longbridge.com/en/news/293458112.md)
- [SMMT: Ivonescimab advances in Phase III, but funding shortfall raises going concern risk](https://longbridge.com/en/news/293661623.md)
- [Alvotech says FDA closes Reykjavik plant inspection with VAI classification](https://longbridge.com/en/news/294215716.md)
- [Alvotech announces successful closure of FDA inspection of manufacturing facility | ALVO Stock News](https://longbridge.com/en/news/294216022.md)